Vestal Point Capital, LP 13F: Quarter-over-Quarter Portfolio Changes
Vestal Point Capital, LP reported a disclosed portfolio value of approximately $4.3 billion in its latest SEC Form 13F-HR filing for Q2 2026, up 19.6% quarter on quarter. Over the quarter, the fund initiated 11 new positions, bought more shares in 31 holdings, trimmed 21 holdings, and exited 33 positions.
Vestal Point Capital, LP's top buy was a new stake in Abbott Laboratories (ABT) , equal to 3.0% of the disclosed portfolio. Its top sell was Revolution Medicines INC (RVMD) . The fund sold 81.1% of its previously reported shares, reducing the position's portfolio weight by 4.5 percentage points.
New PositionsQ2 2026
Securities disclosed for the first time in Q2 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| ABBOTT LABORATORIES | ABT | 3.0% | History → |
| ASCENDIS PHARMA A/S | ASND | 2.3% | Holders → |
| INSMED INC | INSM | 0.6% | Holders → |
| FIRST TRACKS BIOTHERAPEUTICS | TRAX | 0.5% | Holders → |
| AVALO THERAPEUTICS INC | AVTX | 0.3% | Holders → |
| EVOMMUNE INC | EVMN | 0.3% | Holders → |
| KAILERA THERAPEUTICS INC | KLRA | 0.3% | Holders → |
| IBIO INC | IBIO | 0.1% | Holders → |
| SAGIMET BIOSCIENCES INC | SGMT | 0.1% | Holders → |
| ENGENE THERAPEUTICS INC | ENGN | 0.1% | Holders → |
| REZOLUTE INC | RZLT | 0.0% | Holders → |
Top BuysQ2 2026
Showing the top 10 buys among 31 existing positions where the fund bought more shares in Q2 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| INSULET CORP | PODD | +2.1% | +1224.1% | Holders → |
| ZIMMER BIOMET HOLDINGS INC | ZBH | +2.3% | +636.8% | Holders → |
| UNITED THERAPEUTICS CORP DEL | UTHR | +4.3% | +480.0% | History → |
| TARSUS PHARMACEUTICALS INC | TARS | +1.2% | +425.0% | Holders → |
| ASTRAZENECA PLC | AZN | +1.4% | +350.0% | Holders → |
| NEKTAR THERAPEUTICS | NKTR | +1.1% | +250.9% | Holders → |
| MYRIAD GENETICS INC | MYGN | +0.6% | +248.0% | Holders → |
| UNIQURE NV | QURE | +0.8% | +160.4% | Holders → |
| ZURA BIO LTD | ZURA | +0.1% | +129.7% | Holders → |
| DISC MEDICINE INC | IRON | +1.4% | +121.4% | Holders → |
Top SellsQ2 2026
Showing the top 10 sells among 21 existing positions where the fund sold shares in Q2 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| REVOLUTION MEDICINES INC | RVMD | -4.5% | 81.1% | Holders → |
| ALTO NEUROSCIENCE INC | ANRO | -0.8% | 62.0% | Holders → |
| SOLID BIOSCIENCES INC | SLDB | -0.5% | 56.8% | Holders → |
| REPLIGEN CORP | RGEN | -1.8% | 56.8% | Holders → |
| RAPPORT THERAPEUTICS, INC. | RAPP | -0.5% | 49.2% | Holders → |
| ALCON AG | ALC | -0.9% | 37.5% | Holders → |
| IMMUNOCORE HLDGS PLC | IMCR | -1.0% | 34.9% | Holders → |
| ARROWHEAD PHARMACEUTICALS IN | ARWR | -1.0% | 30.8% | History → |
| BETA BIONICS INC | BBNX | -0.0% | 27.7% | Holders → |
| VIKING THERAPEUTICS INC | VKTX | -0.2% | 25.6% | Holders → |
Full ExitsQ2 2026
Positions present in the prior 13F-HR filing that no longer appear in Q2 2026.
Net Portfolio Value ChangeQ2 2026
- $3.6BPrior quarter
- $4.3BCurrent quarter
- +$0.7BNet delta
- +19.6%% change
Methodology & FAQ
How Vestal Point Capital, LP Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Vestal Point Capital, LP: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description, including how confidential treatment filings are handled, is documented in the Methodology.
What stocks did Vestal Point Capital, LP buy in Q2 2026?
In Q2 2026, Vestal Point Capital, LP initiated 11 new positions (ABBOTT LABORATORIES (ABT), ASCENDIS PHARMA A/S (ASND), INSMED INC (INSM), FIRST TRACKS BIOTHERAPEUTICS (TRAX), AVALO THERAPEUTICS INC (AVTX), EVOMMUNE INC (EVMN), KAILERA THERAPEUTICS INC (KLRA), IBIO INC (IBIO), SAGIMET BIOSCIENCES INC (SGMT), ENGENE THERAPEUTICS INC (ENGN), REZOLUTE INC (RZLT)); bought more shares of INSULET CORP (PODD), ZIMMER BIOMET HOLDINGS INC (ZBH), UNITED THERAPEUTICS CORP DEL (UTHR), TARSUS PHARMACEUTICALS INC (TARS), ASTRAZENECA PLC (AZN) (the largest 5 of 31 adds).
What stocks did Vestal Point Capital, LP sell in Q2 2026?
In Q2 2026, Vestal Point Capital, LP fully sold 33 positions (APOGEE THERAPEUTICS INC (APGE), ASCENDIS PHARMA A/S (SYN_04351P101), SCHOLAR ROCK HLDG CORP (SRRK), VERA THERAPEUTICS INC (VERA), TERNS PHARMACEUTICALS INC (TERN), BOSTON SCIENTIFIC CORP (BSX), NUVALENT INC (NUVL), COGENT BIOSCIENCES INC (COGT), CELLDEX THERAPEUTICS INC NEW (CLDX), KALVISTA PHARMACEUTICALS (KALV), PROTAGONIST THERAPEUTICS INC (PTGX), DENALI THERAPEUTICS INC. (DNLI), WATERS CORP (WAT), INSPIRE MED SYS INC (INSP), SOLENO THERAPEUTICS INC (SLNO), CYTOKINETICS INC (CYTK), WEST PHARMACEUTICAL SVSC INC (WST), GENEDX HOLDINGS CORP (WGS), AGIOS PHARMACEUTICALS INC (AGIO), ENGENE THERAPEUTICS INC (SYN_29286M105), ARVINAS INC (ARVN), MAPLIGHT THERAPEUTICS INC (MPLT), FULCRUM THERAPEUTICS INC (FULC), CANDEL THERAPEUTICS INC (CADL), VERACYTE INC (VCYT), GERON CORP (GERN), NOVOCURE LTD (NVCR), UROGEN PHARMA LTD (URGN), PASSAGE BIO INC (PASG), TYRA BIOSCIENCES INC (TYRA), REGENXBIO INC (RGNX), MACROGENICS INC (MGNX), ABSCI CORPORATION (ABSI)); reduced holdings in REVOLUTION MEDICINES INC (RVMD), ALTO NEUROSCIENCE INC (ANRO), SOLID BIOSCIENCES INC (SLDB), REPLIGEN CORP (RGEN), RAPPORT THERAPEUTICS, INC. (RAPP) (the largest 5 of 21 reductions).
Which positions did Vestal Point Capital, LP initiate in Q2 2026?
Vestal Point Capital, LP established 11 new positions in Q2 2026: ABBOTT LABORATORIES (ABT, 3.0%), ASCENDIS PHARMA A/S (ASND, 2.3%), INSMED INC (INSM, 0.6%), FIRST TRACKS BIOTHERAPEUTICS (TRAX, 0.5%), AVALO THERAPEUTICS INC (AVTX, 0.3%), EVOMMUNE INC (EVMN, 0.3%), KAILERA THERAPEUTICS INC (KLRA, 0.3%), IBIO INC (IBIO, 0.1%), SAGIMET BIOSCIENCES INC (SGMT, 0.1%), ENGENE THERAPEUTICS INC (ENGN, 0.1%), REZOLUTE INC (RZLT, 0.0%).
Which existing positions saw the largest allocation increases for Vestal Point Capital, LP in Q2 2026?
Of 31 existing positions with share-count increases in Q2 2026, the largest were: INSULET CORP (PODD, +2.1% weight, +1224.1% shares), ZIMMER BIOMET HOLDINGS INC (ZBH, +2.3% weight, +636.8% shares), UNITED THERAPEUTICS CORP DEL (UTHR, +4.3% weight, +480.0% shares), TARSUS PHARMACEUTICALS INC (TARS, +1.2% weight, +425.0% shares), ASTRAZENECA PLC (AZN, +1.4% weight, +350.0% shares), NEKTAR THERAPEUTICS (NKTR, +1.1% weight, +250.9% shares), MYRIAD GENETICS INC (MYGN, +0.6% weight, +248.0% shares), UNIQURE NV (QURE, +0.8% weight, +160.4% shares), ZURA BIO LTD (ZURA, +0.1% weight, +129.7% shares), DISC MEDICINE INC (IRON, +1.4% weight, +121.4% shares).
Which positions did Vestal Point Capital, LP fully exit in Q2 2026?
Vestal Point Capital, LP fully exited 33 positions in Q2 2026: APOGEE THERAPEUTICS INC (APGE, last-reported weight 2.6%), ASCENDIS PHARMA A/S (SYN_04351P101, last-reported weight 2.4%), SCHOLAR ROCK HLDG CORP (SRRK, last-reported weight 1.8%), VERA THERAPEUTICS INC (VERA, last-reported weight 1.5%), TERNS PHARMACEUTICALS INC (TERN, last-reported weight 1.5%), BOSTON SCIENTIFIC CORP (BSX, last-reported weight 1.4%), NUVALENT INC (NUVL, last-reported weight 1.4%), COGENT BIOSCIENCES INC (COGT, last-reported weight 1.3%), CELLDEX THERAPEUTICS INC NEW (CLDX, last-reported weight 1.1%), KALVISTA PHARMACEUTICALS (KALV, last-reported weight 1.0%), PROTAGONIST THERAPEUTICS INC (PTGX, last-reported weight 1.0%), DENALI THERAPEUTICS INC. (DNLI, last-reported weight 1.0%), WATERS CORP (WAT, last-reported weight 0.8%), INSPIRE MED SYS INC (INSP, last-reported weight 0.8%), SOLENO THERAPEUTICS INC (SLNO, last-reported weight 0.7%), CYTOKINETICS INC (CYTK, last-reported weight 0.6%), WEST PHARMACEUTICAL SVSC INC (WST, last-reported weight 0.5%), GENEDX HOLDINGS CORP (WGS, last-reported weight 0.4%), AGIOS PHARMACEUTICALS INC (AGIO, last-reported weight 0.4%), ENGENE THERAPEUTICS INC (SYN_29286M105, last-reported weight 0.4%), ARVINAS INC (ARVN, last-reported weight 0.3%), MAPLIGHT THERAPEUTICS INC (MPLT, last-reported weight 0.2%), FULCRUM THERAPEUTICS INC (FULC, last-reported weight 0.2%), CANDEL THERAPEUTICS INC (CADL, last-reported weight 0.2%), VERACYTE INC (VCYT, last-reported weight 0.1%), GERON CORP (GERN, last-reported weight 0.1%), NOVOCURE LTD (NVCR, last-reported weight 0.1%), UROGEN PHARMA LTD (URGN, last-reported weight 0.1%), PASSAGE BIO INC (PASG, last-reported weight 0.1%), TYRA BIOSCIENCES INC (TYRA, last-reported weight 0.1%), REGENXBIO INC (RGNX, last-reported weight 0.0%), MACROGENICS INC (MGNX, last-reported weight 0.0%), ABSCI CORPORATION (ABSI, last-reported weight 0.0%).
Which existing positions saw the largest allocation reductions for Vestal Point Capital, LP in Q2 2026?
Of 21 existing positions with share-count reductions in Q2 2026, the largest were: REVOLUTION MEDICINES INC (RVMD, -4.5% weight, -81.1% shares), ALTO NEUROSCIENCE INC (ANRO, -0.8% weight, -62.0% shares), SOLID BIOSCIENCES INC (SLDB, -0.5% weight, -56.8% shares), REPLIGEN CORP (RGEN, -1.8% weight, -56.8% shares), RAPPORT THERAPEUTICS, INC. (RAPP, -0.5% weight, -49.2% shares), ALCON AG (ALC, -0.9% weight, -37.5% shares), IMMUNOCORE HLDGS PLC (IMCR, -1.0% weight, -34.9% shares), ARROWHEAD PHARMACEUTICALS IN (ARWR, -1.0% weight, -30.8% shares), BETA BIONICS INC (BBNX, -0.0% weight, -27.7% shares), VIKING THERAPEUTICS INC (VKTX, -0.2% weight, -25.6% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.